Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 5/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31754346 | 0.88 | SLC1A2 (0.39) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL4594561 | 0.83 | DPP7 (0.48) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL4594803 | 0.83 | DPP7 (0.48) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL9045357 | 0.77 | DPP7 (0.43) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL6500352 | 0.77 | DPP7 (0.43) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL24458242 | 0.76 | DPP7 (0.46) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL30312063 | 0.76 | GRIK1 (0.49) | DPP7SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL32663027 | 0.75 | SLC1A2 (0.47) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL29581742 | 0.74 | — | — | |
| SCHEMBL3232157 | 0.73 | DPP7 (0.55) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | DPP7 1691/4885SLC15A1 3363/4885SLC1A2 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.